Narsoplimab
Modify Date: 2024-01-07 12:03:13
Narsoplimab structure
|
Common Name | Narsoplimab | ||
|---|---|---|---|---|
| CAS Number | 2108782-45-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of NarsoplimabNarsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2[1]. |
| Name | Narsoplimab |
|---|
| Description | Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Narsoplimab (100 nM; 3 h; Vero E6 细胞和带有 SARS-CoV-2 的 Vero E6 细胞) 抑制了 N 蛋白增强的 MASP-2 沉积[1]。 |
| In Vivo | Narsoplimab (10 mg/kg; i.v.; WT and Masp2-/- (KO) mice) 降低了小鼠淋巴细胞百分比 (Lym%)，增加了中性粒细胞百分比 (Neu%)[1]。 Animal Model: WT and Masp2-/- (KO) mice (C57BL/6N, female, 12-15 weeks old)[1] Dosage: 10 mg/kg Administration: Intravenous injection Result: Decreased percentage of lymphocytes (Lym%) and an increased percentage of neutrophils (Neu%). |
| References |
| No Any Chemical & Physical Properties |